Literature DB >> 1491385

The effects of methotrexate on interleukin 1 in patients with rheumatoid arthritis.

D M Chang1, M E Weinblatt, P H Schur.   

Abstract

The effect of methotrexate (MTX) treatment on patients with rheumatoid arthritis on interleukin 1 (IL-1) was evaluated. Eight patients received a weekly MTX dose of 7.5 mg for 6 weeks; none received concomitant corticosteroids. Peripheral blood was obtained 1 day before and 1 day after their weekly MTX dose at Week 1 and 6, isolated monocytes stimulated ex vivo with 1 mg/ml zymosan for 18 h and IL-1 measured by bioassay. Serum and plasma IL-1 levels were measured by immunoassay. Four patients manifested a sharp decrease in IL-1 production 6 weeks after MTX administration associated with a decrease in the number of painful but not swollen joints. No effect on blood levels was observed. Our results suggest that MTX may affect IL-1 production and IL-1 mediated events in some patients.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1491385

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


  10 in total

Review 1.  Combination therapy for autoimmune diseases: the rheumatoid arthritis model.

Authors:  N Fathy; D E Furst
Journal:  Springer Semin Immunopathol       Date:  2001

2.  Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression.

Authors:  M F Neurath; K Hildner; C Becker; J F Schlaak; K Barbulescu; T Germann; E Schmitt; P Schirmacher; S Haralambous; M Pasparakis; K H Meyer Zum Büschenfelde; G Kollias; E Märker-Hermann
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

Review 3.  Mechanistic biomarkers for clinical decision making in rheumatic diseases.

Authors:  William H Robinson; Tamsin M Lindstrom; Regina K Cheung; Jeremy Sokolove
Journal:  Nat Rev Rheumatol       Date:  2013-02-19       Impact factor: 20.543

4.  Methotrexate inhibits interleukin-6 production in patients with juvenile rheumatoid arthritis.

Authors:  Amita Aggarwal; Ramnath Misra
Journal:  Rheumatol Int       Date:  2003-03-07       Impact factor: 2.631

Review 5.  Clinical pharmacology and modification of autoimmunity and inflammation in rheumatoid disease.

Authors:  R Luqmani; C Gordon; P Bacon
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

Review 6.  Methotrexate in rheumatoid arthritis. An update.

Authors:  B Bannwarth; L Labat; Y Moride; T Schaeverbeke
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

7.  Divergent effects of methotrexate on the clonal growth of T and B lymphocytes and synovial adherent cells from patients with rheumatoid arthritis.

Authors:  A Nakajima; M Hakoda; H Yamanaka; N Kamatani; S Kashiwazaki
Journal:  Ann Rheum Dis       Date:  1996-04       Impact factor: 19.103

Review 8.  Pharmacomicrobiology of Methotrexate in Rheumatoid Arthritis: Gut Microbiome as Predictor of Therapeutic Response.

Authors:  Huanhuan Yan; Rui Su; Hongwei Xue; Chong Gao; Xiaofeng Li; Caihong Wang
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 7.561

Review 9.  Molecular mechanism of action and pharmacokinetic properties of methotrexate.

Authors:  V Maksimovic; Z Pavlovic-Popovic; S Vukmirovic; J Cvejic; A Mooranian; H Al-Salami; M Mikov; S Golocorbin-Kon
Journal:  Mol Biol Rep       Date:  2020-05-15       Impact factor: 2.316

Review 10.  Molecular action of methotrexate in inflammatory diseases.

Authors:  Edwin S L Chan; Bruce N Cronstein
Journal:  Arthritis Res       Date:  2002-03-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.